Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Grit Science Completes $30+ Million Series A for Gene Therapy Products

publication date: Mar 3, 2022

Beijing Grit Science completed a Series A funding that raised "hundreds of millions of RMB" (at least $30 million) for its gene therapy operations. Founded in 2019, the company plans to apply its AAV gene therapy technology to liver diseases and neurological disorders, building a pipeline for both rare and common diseases. Grit has already developed an AAV gene therapy for hemophilia A that has started an investigator-led trial. It said the early readout of the novel candidate showed positive safety and efficacy data. The A round financing was led by Sequoia Capital China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital